文献速递浆细胞疾病

靶向Erk1/2与CDK4/6抑制剂联合治疗复发难治性多发性骨髓瘤

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
PubMed 文献 · Leukemia · 2022-01-27

研究在复发难治性多发性骨髓瘤中检测Erk1/2抑制剂联合CDK4/6抑制剂的抗骨髓瘤效应。结果显示两药联合在骨髓瘤细胞中呈强协同细胞毒性(IC<0.5),剂量依赖性将细胞阻滞于G0/G1期并激活线粒体凋亡信号,抑制c-myc、p-RSK、p-S6、p-RB和E2F1等靶分子,并鉴定出包含SNRPB和SLC25A5的五基因特征。作者认为该结果为Erk1/2抑制剂联合CDK4/6抑制剂靶向Ras+CDK通路的临床试验提供了临床前框架。

要点

  • Erk1/2抑制剂联合CDK4/6抑制剂在骨髓瘤细胞中呈强协同细胞毒性(IC<0.5)。
  • 联合治疗剂量依赖性将骨髓瘤细胞阻滞于G0/G1期并激活线粒体凋亡信号。
  • 联合治疗抑制c-myc、p-RSK、p-S6、p-RB和E2F1,提示靶向活性。

核心结论

  • 研究结果为Erk1/2抑制剂联合CDK4/6抑制剂靶向Ras+CDK通路改善多发性骨髓瘤患者结局的临床试验提供了临床前框架。

研究设计与样本

  • 临床前研究,检测Erk1/2抑制剂联合CDK4/6抑制剂对多发性骨髓瘤细胞的抗骨髓瘤效应。

主要发现

  • Erk1/2抑制剂联合CDK4/6抑制剂在骨髓瘤细胞中呈强协同细胞毒性(IC<0.5)。
  • 联合治疗剂量依赖性将骨髓瘤细胞阻滞于G0/G1期并激活线粒体凋亡信号。
  • 联合治疗抑制Erk1/2和CDK4/6信号通路关键靶分子c-myc、p-RSK、p-S6、p-RB和E2F1,提示靶向活性。
  • 鉴定出联合治疗相关的五基因特征,包含SNRPB和SLC25A5,分别参与RNA加工和线粒体代谢。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oncogenic activated RAS mutations have been detected in 50% of de novo and 70% of relapsed multiple myeloma (MM) patients. Translocation t(11;14) involving IgH/CCDN1 and overexpression of cyclin-Ds are early events in MM pathogenesis, enhancing uncontrolled MM cell growth. We hypothesized that targeting both RAS/MAPK pathway molecules including Erk1/2 along with cyclin-Ds enhances MM cytotoxicity and minimizes side effects. Recent studies have demonstrated the high potency of Erk1/2 and CDK4/6 inhibitors in metastatic relapsed cancers, and here we tested anti-MM effects of the Erk1/2 + CDK4/6 inhibitor combination. Our studies showed strong synergistic (IC < 0.5) cytotoxicity of Erk1/2i + CDK4/6i in MM-cells. Erk1/2i + CDK4/6i treatment in a dose-dependent manner arrested MM-cells in the G0/G1 phase and activated mitochondrial apoptotic signaling. Our studies showed that Erk1/2i + CDK4/6i treatment-induced inhibition of key target molecules in Erk1/2 and CDK4/6 signaling, such as c-myc, p-RSK, p-S6, p-RB, and E2F1, suggesting on-target activity of these inhibitors. We identified Erk1/2i + CDK4/6i treatment associated five-gene signature which includes SNRPB and SLC25A5; these genes are involved in RNA processing and mitochondrial metabolism, respectively. Overall, our studies provide the preclinical framework for Erk1/2i + CDK4/6i combination clinical trials to target Ras+CDK pathways to improve patient outcome in MM.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Adamia S, Bhatt S, Wen K, et al. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia. 2022. PMID: 35082402. doi:10.1038/s41375-021-01475-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。